EPOK Therapeutics
A Stealth Biotech with a Global Vision

A global reach is vital for biotech startups to leverage R&D expertise, develop therapeutics for underserved regions, and maximize commercial opportunity. EPOK Therapeutics, an innovative biotech startup specializing in the discovery and development of biologics to treat metabolic diseases, exemplifies this imperative by rapidly expanding beyond the borders of Canada.

Guided by the leadership of Dr. Sachdev Sidhu, Chief Scientific Officer (CSO) of EPOK, the firm is at the forefront of advanced biologics by predominantly focusing on novel engineered antibody variants to address precise medical requirements. The company’s current therapeutic portfolio addresses the limitations of current treatments for anemia and phosphate disorders linked to genetic and acquired diseases. To counter the challenges associated with these conditions, proprietary drug candidates are currently in the preclinical stages of development.

EPOK, originating in Canada, exerts influence beyond national borders, with its financial strength attributed to substantial funding from Italy and various geographical regions.

The company’s presence spans the innovation hubs of the Bay Area in California and Texas and several development partners in the US and Europe, reinforcing its commitment to maintaining a global drug discovery and development perspective. EPOK has established a vital collaboration with Dr. Orson Moe at the University of Texas Southwestern Medical Center, a renowned institution specializing in metabolic diseases. In addition, its management team consists of pharma veterans positioned in California, a biotech hub, and Italy, leveraging local Pharma and biotech ecosystems to deliver exceptional and effective drugs.

Through these global partnerships and the development of an innovative molecule, EPOK has demonstrated swift progression from breakthrough science to therapeutic candidates, highlighting the success of the company’s business model.

“Our mission is to enhance the global accessibility and affordability of medicines, targeting areas where current medications are underutilized,” said Surya Sankuratri, CEO of EPOK Therapeutics.

Guided by robust science, therapeutic efficacy, core safety, convenience, and affordability principles, the company’s drug research employs innovative approaches such as less frequent drug dosing, economical pricing, and improved storage stability to reach a wider global population.

By introducing novel mechanisms, EPOK also overcomes existing drug limitations and expands the range of patients eligible for EPOK.

Notably, EPOK has set a timeline for its lead drug candidate, with an anticipated entry of testing in patients within the next 18 months. In addition, the company strongly emphasizes safe lead candidates to be highly selective for the target, thus minimizing off-target actions and preventing unintended consequences observed with approved treatments. Contract research laboratories specializing in different fields allow the company to reduce costs and maximize development speed.

Sidhu further emphasizes, “Stellar science, extensive antibody engineering experience, and effective management are key contributors to our rapid growth and ongoing success.”

Looking ahead, EPOK aims to remain location-agnostic, actively exploring connections in Asia while focusing on collaborations with global leaders. The pursuit of excellence beyond borders, with a substantial footprint in Europe and the USA, defines the firm’s commitment to assembling the best components irrespective of geographical constraints and pushing the boundaries of pharmaceutical innovation on a global scale.